Open-label, long-term tolerability of naratriptan for short-term prevention of menstrually related migraine

Headache

Volumn 47, Issue 6, 2007, Pages 886-894

  Brandes, Jan Lewis ^a,b   Smith, Timothy ^c   Diamond, Merle ^d   Ames, Michael H ^e  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Nashville Neuroscience Group   (United States)

^c Ryan Headache Center   (United States)

^d DIAMOND HEADACHE CLINIC   (United States)

^e GLAXOSMITHKLINE   (United States)

Author keywords

Intermittent prophylaxis; Menstrually related migraine; Naratriptan; Short term prevention; Tolerability

Indexed keywords

NARATRIPTAN;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CHEMOPROPHYLAXIS; CLINICAL LABORATORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISABILITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EAR NOSE THROAT DISEASE; ECG ABNORMALITY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEADACHE; HUMAN; INCIDENCE; INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALAISE; MEDICAL SOCIETY; MENSTRUAL CYCLE; MENSTRUAL MIGRAINE; MENTAL HEALTH; MIGRAINE; MIGRAINE AURA; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PAIN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SHORT COURSE THERAPY; SIDE EFFECT; THORAX DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS INFECTION; VITAL SIGN;

ADULT; FEMALE; HUMANS; MENSTRUATION; MIDDLE AGED; MIGRAINE DISORDERS; PIPERIDINES; SEROTONIN AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 34250688788     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2007.00809.x     Document Type: Article

References (20)

1. Loder E. Prophylaxis of menstrual migraine with triptans: Problems and possibilities. Neurology. 2002 59 : 1677 1681.
2. MacGregor EA, Hackshaw A. Prevalence of migraine on each day of the menstrual cycle. Neurology. 2004 63 : 351 353.
3. Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni G. Migraine without aura and reproductive life events: A clinical epidemiological study in 1300 women. Headache. 1993 33 : 385 389.
4. Fettes I. Menstrual migraine: Methods of prevention and control. Postgrad Med. 1997 101 : 67 70, 73 77.
5. Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002 22 : 633 658.
6. Newman LC, Lipton RB, Lay CL, Solomon S. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology. 1998 51 : 307 309.
7. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually-related migraine: A randomized, double-blind, placebo-controlled study. Headache. 2001 41 : 248 256.
8. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004 63 : 261 269.
9. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: A double-blind, placebo-controlled study. Headache. 1990 30 : 705 709.
10. Brandes JL. The influence of estrogen on migraine: Current understanding and future direction. JAMA. 2006 295 : 1824 1830.
11. Savani N, Loftus J, Mansbach H, Scott A. A randomised, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Poster Presentation at the 6th European Headache Congress, Istanbul, Turkey. June 17, 2002 - June 22, 2002.
12. Nett R, Mannix LK, Landy S, Shackelford S, Jobsis M. A randomised, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1 mg twice daily as prophylactic treatment for menstrually-associated migraine. Neurology. 2003 60 (5 suppl 1 A95 Abs No S15.006.
13. Mathew NT, Asgharnejad M, Peykamian M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine: Results of a double-blind, placebo-controlled crossover study. Neurology. 1997 49 : 1485 1490.
14. Klassen A, Elkind A, Asgharnejad M, et al. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled, parallel-group study. Headache. 1997 37 : 640 645.
15. Heywood J, Bomhof MA, Pradalier A, et al. Tolerability and efficacy of naratriptan tablets in the acute treatment of migraine attacks for 1 year. Cephalalgia. 2000 20 : 470 474.
16. Headache Classification Committee of the International Headache Society. Classification of headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988 8 (suppl 7 1 96.
17. Headache Classification Subcommittee of the International Headache Society. International classification of headache disorders. Cephalalgia. 2004 24 (suppl 1 1 160.
18. Tuchman M, Hee A, Emeribe U. Oral zolmitrptan 2.5 mg demonstrates high efficacy and good tolerability in the prophylactic treatment of menstrual migraine headaches. Headache. 2005 45 : 771 772.
19. Gammaitoni A, Tobin J, Shaw R, Campbell J. Frovatriptan for the prevention of menstrual migraine headaches: Results of a 12-month open-label safety and tolerability study. Neurology. 2006 66 : A224.
20. Kosinski M, Bjorner J, Bayliss MS, et al. Measuring the impact of migraine and severe headache: With the Headache Impact Test (HIT) using the response theory models to score widely-used measures of headache impact. Paper presented: 52nd Annual Meeting, American Academy of Neurology May 4, 2000 San Diego, CA.